Conmed (NYSE: CNMD) reported Q1 EPS of $0.79, $0.05 better than the analyst estimate of $0.74. Revenue for the quarter came in at $312.3 million versus the consensus estimate of $306.73 million.

GUIDANCE:

Conmed sees FY2024 EPS of $4.25-$4.35, versus the consensus of $4.33. Conmed sees FY2024 revenue of $1.33-1.355 billion, versus the consensus of $1.35 billion.

For earnings history and earnings-related data on Conmed (CNMD) click here.